Production (Stage)
Mydecine Innovations Group Inc.
MYCO
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.62M | 1.81M | 2.63M | 2.86M | 3.92M |
| Depreciation & Amortization | -- | -- | 0.00 | 900.00 | 3.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.66M | 1.86M | 5.13M | 4.59M | 4.63M |
| Operating Income | -1.66M | -1.86M | -5.13M | -4.59M | -4.63M |
| Income Before Tax | -1.82M | -2.36M | -9.15M | -8.57M | -8.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.82 | -2.36 | -9.15 | -8.57 | -8.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.82M | -2.36M | -9.15M | -8.57M | -8.50M |
| EBIT | -1.66M | -1.86M | -5.13M | -4.59M | -4.63M |
| EBITDA | -1.39M | -1.85M | -5.12M | -4.58M | -4.62M |
| EPS Basic | -0.03 | -0.04 | -0.17 | -0.18 | -0.22 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.11 | -0.11 | -0.14 |
| EPS Diluted | -0.03 | -0.04 | -0.17 | -0.18 | -0.22 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.11 | -0.11 | -0.14 |
| Average Basic Shares Outstanding | 246.33M | 238.38M | 226.21M | 193.21M | 157.17M |
| Average Diluted Shares Outstanding | 246.33M | 238.38M | 226.21M | 193.21M | 157.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |